Quick answer: how AOD-9604 compares to tirzepatide
- Evidence: Tirzepatide has large human trials with average weight loss roughly 15–22% at 72 weeks (dose and population dependent). AOD‑9604 lacks comparable high‑quality human data for weight loss.
- Status in Australia: Tirzepatide is prescription‑only and TGA‑approved (brands include Mounjaro; a weight‑management brand Zepbound has also been approved, with availability dependent on rollout). AOD‑9604 is unapproved for weight loss; therapeutic supply is regulated and consumer sale/import is risky.
- Safety: Tirzepatide has a well‑characterised side‑effect profile and clinical monitoring requirements. AOD‑9604 has limited human safety data; product quality varies in grey markets.
- Bottom line: For medical weight management, tirzepatide is the evidence‑based pathway via a prescription. AOD‑9604 remains an experimental topic without robust clinical support for weight loss.
What each option is and how they differ
AOD-9604 (HGH fragment 176‑191)
- Type: Synthetic peptide fragment derived from human growth hormone (sequence 176–191).
- Claimed mechanism: Marketed to promote lipolysis and reduce lipogenesis without raising IGF‑1. Evidence is largely preclinical or low‑quality human data.
- Regulatory status: Not TGA‑approved for weight loss. Therapeutic use is regulated; consumer sales/imports carry legal and seizure risk in Australia.
Learn more: What Is AOD‑9604? • AOD‑9604 Benefits • AOD‑9604 Side Effects • Is AOD‑9604 Legal in Australia?
Tirzepatide (dual GIP/GLP‑1 receptor agonist)
- Type: Prescription medicine that activates GIP and GLP‑1 receptors to reduce appetite, improve glycaemic control and support weight reduction.
- Evidence: Large randomised trials show substantial average weight loss in people with obesity and additional benefits in those with type 2 diabetes.
- Regulatory status: TGA‑approved prescription medicine in Australia (Mounjaro for T2D; weight‑management brand Zepbound also approved; availability depends on supply).
Explore details: What Is Tirzepatide? • Benefits • Side Effects • Is Tirzepatide Legal in Australia?
Results and evidence: AOD‑9604 vs tirzepatide
AOD‑9604
- Human data: No large, high‑quality, peer‑reviewed RCTs demonstrating clinically meaningful weight loss in the general population.
- Takeaway: Evidence for fat loss in humans remains limited and inconsistent.
Tirzepatide
- Obesity trials: Average weight reductions in the mid‑teens to low‑twenties (% of body weight) over ~72 weeks, depending on dose and cohort.
- Diabetes trials: Significant weight loss alongside improvements in glycaemic control versus comparators.
- Lifestyle: Best results occur with dietary support, activity changes and adherence to a medical plan.
Compare related guides: AOD‑9604 vs Semaglutide • Semaglutide vs Tirzepatide Weight Loss • GLP‑1 Australia Guide • Weight Loss Injections Australia
Safety and side effects
AOD‑9604
- Profile: Limited human safety data; variable product quality and dosing in grey markets increase uncertainty.
- Monitoring: No established, regulator‑endorsed monitoring framework for weight loss.
Tirzepatide
- Common effects: Nausea, vomiting, diarrhoea or constipation during dose escalation; typically improve over time with clinician‑guided titration.
- Warnings: Screening for pancreatitis history, gallbladder disease, certain thyroid conditions and other risk factors is important. Use is prescription‑only with medical supervision.
Read more: Tirzepatide Side Effects • AOD‑9604 Side Effects
Legality and access in Australia
AOD‑9604
- Approval: Not approved by the TGA for weight loss.
- Supply: Therapeutic supply is regulated. Consumer sales and personal importation are risky and may result in seizure or penalties.
- Next step: If you are researching AOD‑9604, read legal guidance first and speak with a clinician.
Guides: Is AOD‑9604 Legal in Australia? • Buy AOD‑9604 Australia • AOD‑9604 Prescription Australia
Tirzepatide
- Approval: TGA‑approved prescription medicine. Access requires a valid script from a registered prescriber.
- Brands: Mounjaro (T2D). A weight‑management brand (Zepbound) is also approved; rollout depends on supply.
- Pathway: Medical assessment, eligibility screening, ongoing monitoring and pharmacy fulfilment.
Access pages: Buy Tirzepatide Australia • Tirzepatide Prescription Australia • Tirzepatide for Weight Loss
Cost and availability
- AOD‑9604: Pricing varies widely in grey or semi‑regulated channels. Quality and strength can be inconsistent. See our cost and access warnings.
- Tirzepatide: Private pricing depends on brand, dose and pharmacy availability. Supply constraints can occur. Eligibility, dosing plans and follow‑up affect total cost.
Further reading: AOD‑9604 Cost Australia • Tirzepatide Cost Australia • Peptide Clinic Cost Australia
Which is more suitable for common goals?
- Medically supervised weight loss with evidence: Tirzepatide (dual GIP/GLP‑1) via prescription and structured care.
- Exploring experimental fat‑loss claims: AOD‑9604 remains unapproved with limited human data; legal and quality risks should be understood first.
- If you have type 2 diabetes: Tirzepatide has strong data for glycaemic control and weight loss; a clinician can compare against GLP‑1 options such as semaglutide.
- If you want alternatives: See our guides on semaglutide vs tirzepatide, retatrutide vs tirzepatide and cagrilintide vs tirzepatide.
Frequently asked questions
Is AOD-9604 better than tirzepatide for fat loss?
No. Tirzepatide has strong human evidence and is an approved prescription medicine. AOD‑9604 does not have comparable clinical data for weight loss.
Can I buy AOD-9604 online in Australia?
Consumer sales pitched for therapeutic use are risky and may be unlawful. Personal importation can result in seizure. Read our legal guidance before considering access: Is AOD‑9604 Legal in Australia?
What weight loss can I expect with tirzepatide?
In clinical trials, average reductions of roughly 15–22% of body weight over ~72 weeks have been seen in people with obesity, varying by dose and population. Individual results depend on adherence, dose, diet and medical factors.
How do side effects compare?
Tirzepatide commonly causes transient gastrointestinal effects and requires medical screening and follow‑up. AOD‑9604 has limited human safety data; the main concerns are unknowns and product variability.
What about semaglutide?
Semaglutide (GLP‑1) is another evidence‑based, prescription option. See Semaglutide vs Tirzepatide and AOD‑9604 vs Semaglutide to compare mechanisms, results and side effects.
Who should not use tirzepatide?
People with certain conditions (for example, a history suggestive of pancreatitis, particular thyroid tumours or relevant family history) may be unsuitable. Only a clinician can advise after assessment. Start here: Check eligibility.
Get help: compare options and check eligibility
Have questions about AOD‑9604 vs tirzepatide, legal access or expected results? Send a message and a clinician‑aligned team member will respond.